SEARCH

SEARCH BY CITATION

References

  • 1
    Sampson, J. H., J. H. Carter, A. H. Friedman, and H. F. Seigler. 1998. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88:1120.
  • 2
    Fife, K. M., M. H. Colman, G. N. Stevens, I. C. Firth, D. Moon, K. F. Shannon, et al. 2004. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 22:12931300.
  • 3
    Mathieu, D., D. Kondziolka, P. B. Cooper, J. C. Flickinger, A. Niranjan, S. Agarwala, et al. 2007. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 60:471482.
  • 4
    Liew, D. N., H. Kano, D. Kondziolka, D. Mathieu, A. Niranjan, J. C. Flickinger, et al. 2011. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. J. Neurosurg. 114:769779.
  • 5
    Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711723.
  • 6
    Robert, C., L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364:25172526.
  • 7
    Margolin, K., M. S. Ernstoff, O. Hamid, D. Lawrence, D. McDermott, I. Puzanov, et al. 2012. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13:459465.
  • 8
    Knisely, J. P. S., J. B. Yu, J. Flanigan, M. Sznol, H. M. Kluger, and V. L. S. Chiang. 2012. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117:227233.
  • 9
    Mathew, M., M. Tam, P. A. Ott, A. C. Pavlick, S. C. Rush, B. R. Donahue, et al. 2013. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 23:191195.
  • 10
    Weber, J. S., A. Amin, D. Minor, J. Siegel, D. Berman, and S. J. O'Day. 2011. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 21:530534.
  • 11
    Lao, C., J. Friedman, C. Tsien, D. Normolle, C. Chapman, Y. Cao, et al. 2013. Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiat. Oncol. 8:204.
  • 12
    Staudt, M., K. Lasithiotakis, U. Leiter, F. Meier, T. Eigentler, M. Bamberg, et al. 2010. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 102:12131218.
  • 13
    Eigentler, T. K., A. Figl, D. Krex, P. Mohr, C. Mauch, K. Rass, et al. 2011. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117:16971703.
  • 14
    Lonser, R. R., D. K. Song, J. Klapper, M. Hagan, S. Auh, P. B. Kerr, et al. 2011. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J. Neurosurg. 115:3036.
  • 15
    Du Four, S., S. Wilgenhof, J. Duerinck, A. Michotte, A. V. Binst, M. D. Ridder, et al. 2012. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur. J. Cancer 48:30453051.
  • 16
    Sperduto, P. W., S. T. Chao, P. K. Sneed, X. Luo, J. Suh, D. Roberge, et al. 2010. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int. J. Radiat. Oncol. Biol. Phys. 77:655661.
  • 17
    Eisenhauer, E. A., P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45:228247.
  • 18
    Wolchok, J. D., A. Hoos, S. O'Day, J. S. Weber, O. Hamid, C. Lebbé, et al. 2009. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15:74127420.
  • 19
    Cleves, M., W. W. Gould, R. G. Gutierrez, and Y. Marchenko. 2008. An introduction to survival analysis using Stata. 2nd ed. Stata Press, College Station, TX.
  • 20
    Prins, R. M., D. D. Vo, H. Khan-Farooqi, M.-Y. Yang, H. Soto, J. S. Economou, et al. 2006. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J. Immunol. 177:84488455.
  • 21
    Cao, Y., C. I. Tsien, Z. Shen, D. S. Tatro, R. Ten Haken, M. L. Kessler, et al. 2005. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J. Clin. Oncol. 23:41274136.
  • 22
    Corso, C. D., A. N. Ali, and R. Diaz. 2011. Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am. J. Cancer Res. 1:390412.
  • 23
    Takeshima, T., K. Chamoto, D. Wakita, T. Ohkuri, Y. Togashi, H. Shirato, et al. 2010. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 70:26972706.
  • 24
    Shiao, S., and L. Coussens. 2010. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia 15:411421.
  • 25
    Hamilton, R., M. Krauze, M. Romkes, B. Omolo, P. Konstantinopoulos, T. Reinhard, et al. 2013. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119:27372746.
  • 26
    Dewan, M. Z., A. E. Galloway, N. Kawashima, J. K. Dewyngaert, J. S. Babb, S. C. Formenti, et al. 2009. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15:53795388.
  • 27
    Postow, M. A., M. K. Callahan, C. A. Barker, Y. Yamada, J. Yuan, S. Kitano, et al. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366:925931.
  • 28
    Stamell, E. F., J. D. Wolchok, S. Gnjatic, N. Y. Lee, and I. Brownell. 2013. The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys. 85:293295.
  • 29
    Peduzzi, P., J. Concato, A. R. Feinstein, and T. R. Holford. 1995. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J. Clin. Epidemiol. 48:15031510.
  • 30
    Chapman, P. B., A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:25072516.
  • 31
    Long, G. V., U. Trefzer, M. A. Davies, R. F. Kefford, P. A. Ascierto, P. B. Chapman, et al. 2012. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13:10871095.
  • 32
    Gonzalez-Martinez, J., L. Hernandez, L. Zamorano, A. Sloan, K. Levin, S. Lo, et al. 2002. Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J. Neurosurg. 97:494498.